S.F. biotech inches closer to potential HIV cure with key move by FDA

Using the CRISPR genome-editing technology that won UC Berkeley’s Jennifer Doudna a share of the 2020 Nobel Prize in chemistry, the company has a potential cure for HIV in an early-stage clinical trial.
Click here to view original post